Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Radioterapia Paliativa de Fração Única ou Multifração para a Melhoria da Qualidade de Vida em Pacientes com Câncer Ginecológico Metastático

28 de outubro de 2026 atualizado por: M.D. Anderson Cancer Center

Um estudo randomizado de fase II de radioterapia pélvica paliativa para melhorar a qualidade de vida relacionada à saúde em neoplasias ginecológicas

This phase II trial studies if a single session of palliative radiation therapy can help improve symptoms of gynecologic cancers that have spread to other places in the body (metastatic) and that affect quality of life as well or more so than multiple sessions (which is the standard of care). Palliative radiation therapy may help patients with metastatic gynecologic cancers live more comfortably. Researchers also want to learn how radiation affects the immune system and to compare the effects of giving one radiation treatment to giving multiple radiation treatments.

Visão geral do estudo

Descrição detalhada

PRIMARY OBJECTIVE:

I. To determine whether single fraction palliative radiation therapy (SFRT) improves the proportion of patients with improved Health-Related Quality of Life (HR-QOL) over multi-fraction palliative radiotherapy (MFRT).

SECONDARY OBJECTIVES:

I. To determine whether single fraction palliative radiation therapy (SFRT) improves overall health related quality of life (HR-QOL) over multi fraction palliative radiation therapy (MFRT).

II. To determine whether SFRT improves individual domains of HR-QOL over MFRT.

III. To determine whether SFRT increases clinically meaningful HR-QOL improvement over MFRT.

IV. To determine whether SFRT provides non-inferior symptom burden improvement (SBI) to MFRT.

EXPLORATORY OBJECTIVES:

I. To describe T-cell repertoire of patients receiving SFRT and MFRT.

II. To describe vaginal microbiome of patients receiving SFRT and MFRT.

III. To describe gut microbiome of patients receiving SFRT and MFRT.

IV. To describe financial burden of patients undergoing palliative pelvic radiation with either SFRT or MFRT.

V. To describe financial burden of patients undergoing palliative pelvic radiation with SFRT and MFRT.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM A: Patients undergo standard of care radiation therapy in the form of 3-dimensional conformal radiation therapy (3D CRT), intensity-modulated radiation therapy (IMRT), or volume modulated arc therapy (VMAT) at the physician's discretion for 1 fraction in the absence of disease progression or unacceptable toxicity. Patients with < 30% decrease in the Symptom Inventory Scale (SIS) may receive an additional fraction on day 21 at the physician's discretion.

ARM B: Patients undergo standard of care radiation therapy in the form of 3D CRT, IMRT, or VMAT at the physician's discretion over 2 weeks for 10 fractions in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for up to 1 year.

Tipo de estudo

Intervencional

Inscrição (Real)

28

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • New Jersey
      • Camden, New Jersey, Estados Unidos, 08103
        • Cooper Hospital University
    • Ohio
      • Columbus, Ohio, Estados Unidos, 43215
        • OhioHealth
    • Texas
      • Houston, Texas, Estados Unidos, 77030
        • M D Anderson Cancer Center

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Fêmea

Descrição

Inclusion Criteria:

  • Histologically or cytologically documented gynecologic cancer with prior or current evidence of metastatic disease
  • Measurable pelvic disease with any pain and/or bleeding
  • Eastern Cooperative Oncology Group (ECOG) performance status of =< 3
  • Estimated life expectancy > 3 months at discretion of treating physician
  • Female participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication
  • Patient able to provide properly obtained written informed consent
  • Gynecologic Section Radiation Oncology Quality Assurance (QA) for eligibility for single fraction radiation treatment

Exclusion Criteria:

  • Prior pelvic radiation therapy that would make treatment unsafe at the discretion of the treating physician
  • Systemic therapy concurrently or within 21 days of first dose of radiation
  • Concurrent participation in another interventional radiation therapy trial concurrently or within 30 days of study consent. Note: Patients who are participating in systemic clinical trials and non-interventional clinical trials (e.g., QOL, imaging, observational, follow-up studies, etc.) are eligible, regardless of the timing of participation
  • Known second malignancy that requires active treatment (at the discretion of the primary investigator)
  • Documented psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
  • Pregnant or breastfeeding at any point starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Arm A (radiation therapy)

Patients undergo standard of care radiation therapy in the form of 3D CRT, IMRT, or VMAT at the physician's discretion for 1 fraction in the absence of disease progression or unacceptable toxicity. Patients with < 30% decrease in the SIS may receive an additional fraction on day 21 at the physician's discretion.

Ancillary studies

Outros nomes:
  • Avaliação da Qualidade de Vida

Ancillary studies

Undergo IMRT

Outros nomes:
  • IMRT
  • RT Modulado de Intensidade
  • Radioterapia de Intensidade Modulada
  • Radiação, Radioterapia de Intensidade Modulada

Undergo 3D CRT

Outros nomes:
  • Radioterapia tridimensional
  • TERAPIA DE RADIAÇÃO CONFORMAL 3D
  • CRT 3D
  • 3D-CRT
  • Terapia Conformal
  • Radioterapia Conformal
  • Radiação, 3D Conformal

Undergo VMAT

Outros nomes:
  • VMAT
Comparador Ativo: Arm B (radiation therapy)

Patients undergo standard of care radiation therapy in the form of 3D CRT, IMRT, or VMAT at the physician's discretion over 2 weeks for 10 fractions in the absence of disease progression or unacceptable toxicity.

Ancillary studies

Outros nomes:
  • Avaliação da Qualidade de Vida

Ancillary studies

Undergo IMRT

Outros nomes:
  • IMRT
  • RT Modulado de Intensidade
  • Radioterapia de Intensidade Modulada
  • Radiação, Radioterapia de Intensidade Modulada

Undergo 3D CRT

Outros nomes:
  • Radioterapia tridimensional
  • TERAPIA DE RADIAÇÃO CONFORMAL 3D
  • CRT 3D
  • 3D-CRT
  • Terapia Conformal
  • Radioterapia Conformal
  • Radiação, 3D Conformal

Undergo VMAT

Outros nomes:
  • VMAT

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Absolute change in index value of EuroQol 5 Dimensions - 5 Levels (EQ-5D-5L) score
Prazo: Baseline up to 21 days post-radiation therapy

An index value will be calculated for each participant according to page 13 of the user guide. Scores will be summarized using descriptive statistics. Will use a 2-sample t-test to compare the change scores between the single fraction palliative radiation therapy (SFRT) and multi-fraction palliative radiation therapy (MFRT) groups.

Baseline up to 21 days post-radiation therapy

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Absolute change in mobility
Prazo: Baseline up to 21 days post-radiation therapy

Each dimension is rated on a scale from 1 to 5 where 1 represents no problem present or patient can care for self and 5 represents extreme problems present or unable to care for self. Improvement within each dimension will be assessed by the absolute change of heath state. A decrease in the raw score by 1 or more points denotes improvement within the dimension.

Baseline up to 21 days post-radiation therapy
Absolute change in self-care
Prazo: Baseline up to 21 days post-radiation therapy

Each dimension is rated on a scale from 1 to 5 where 1 represents no problem present or patient can care for self and 5 represents extreme problems present or unable to care for self. Improvement within each dimension will be assessed by the absolute change of heath state. A decrease in the raw score by 1 or more points denotes improvement within the dimension.

Baseline up to 21 days post-radiation therapy
Absolute change in activity
Prazo: Baseline up to 21 days post-radiation therapy

Each dimension is rated on a scale from 1 to 5 where 1 represents no problem present or patient can care for self and 5 represents extreme problems present or unable to care for self. Improvement within each dimension will be assessed by the absolute change of heath state. A decrease in the raw score by 1 or more points denotes improvement within the dimension.

Baseline up to 21 days post-radiation therapy
Absolute change in pain
Prazo: Baseline up to 21 days post-radiation therapy

Each dimension is rated on a scale from 1 to 5 where 1 represents no problem present or patient can care for self and 5 represents extreme problems present or unable to care for self. Improvement within each dimension will be assessed by the absolute change of heath state. A decrease in the raw score by 1 or more points denotes improvement within the dimension.

Baseline up to 21 days post-radiation therapy
Absolute change in anxiety
Prazo: Baseline up to 21 days post-radiation therapy

Each dimension is rated on a scale from 1 to 5 where 1 represents no problem present or patient can care for self and 5 represents extreme problems present or unable to care for self. Improvement within each dimension will be assessed by the absolute change of heath state. A decrease in the raw score by 1 or more points denotes improvement within the dimension.

Baseline up to 21 days post-radiation therapy
>= 6 point increase in EuroQol-Visual Analogue Scale
Prazo: Baseline up to 21 days post-radiation therapy

Will summarize the number of patients with clinical meaningful health-related (HR)-quality of life (QOL) improvement using frequencies and proportions. The proportion of patients with clinically meaningful HR-QOL improvement will be compared between SFRT and MFRT using a chi-squared test.

Baseline up to 21 days post-radiation therapy
Decrease in Symptom Inventory (SIS)
Prazo: At 21 days post-radiation therapy

Will be calculated as the average of the worst pain, least pain, pain on average, pain right now and scores from the vaginal bleeding questions. The change in SIS score from baseline to 21 days post radiation therapy will be calculated for each patient and evaluated between the SFRT and MFRT groups using a t-test. Will be calculated as the average of the worst pain, least pain, pain on average, pain right now and scores from the vaginal bleeding questions. The change in SIS score from baseline to 21 days post radiation therapy will be calculated for each patient and evaluated between the SFRT and MFRT groups using a t-test.

At 21 days post-radiation therapy
Incidence of adverse events
Prazo: Within 21 days and up to 1 year

Assessed per Common Terminology Criteria for Adverse Events version 5.0. Radiation related toxicity event rates within 21 days and within one year for patients receiving SFRT and MFRT will be summarized using frequencies and proportions. Proportions between SFRT and MFRT will be compared using a chi-squared or Fisher's exact test.

Within 21 days and up to 1 year

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
T-cell repertoire
Prazo: Up to 1 year

Will describe T-cell clonality, diversity, clonal overlap, productive and nonproductive frequencies using descriptive statistics. Informal comparisons may be completed to generate hypotheses for future studies.

Up to 1 year
Vaginal microbiome
Prazo: Up to 1 year

Will use alpha and beta diversity metrics for both 16S and whole-genome sequencing (WGS), including overall diversity, richness and evenness and species-specific microbial dynamics. Will be summarized using descriptive statistics. Informal comparisons may be completed to generate hypotheses for future studies.

Up to 1 year
Gut microbiome
Prazo: Up to 1 year

Will use alpha and beta diversity metrics for both 16S and WGS sequencing, including overall diversity, richness and evenness and species-specific microbial dynamics. Will be summarized using descriptive statistics. Informal comparisons may be completed to generate hypotheses for future studies.

Up to 1 year
Financial burden
Prazo: Up to 21 days

Will be assessed using the Economic Strain and Resilience in Cancer Financial Toxicity Questionnaire. The scores for each question will be summarized using descriptive statistics. An overall average score will be calculated by calculating the mean score of the seven questions. At the end of the questionnaire, the patient is asked to rate their overall financial situation as much better, better, nearly the same, worse, or much worse. The frequency of each answer to the global question will be tabulated.

Up to 21 days

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Lauren Colbert, M.D. Anderson Cancer Center

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

11 de janeiro de 2021

Conclusão Primária (Estimado)

31 de dezembro de 2029

Conclusão do estudo (Estimado)

31 de dezembro de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

13 de agosto de 2020

Enviado pela primeira vez que atendeu aos critérios de CQ

13 de agosto de 2020

Primeira postagem (Real)

18 de agosto de 2020

Atualizações de registro de estudo

Última Atualização Postada (Real)

30 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

28 de outubro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • 2020-0517
  • 2020-0517 (Outro identificador: M D Anderson Cancer Center)
  • NCI-2020-05684 (Identificador de registro: CTRP (Clinical Trial Reporting Program))

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever